Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 1251 results for public health guidance

  1. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Bimekizumab for treating ankylosing spondylitis [ID4011]

    Awaiting development Reference number: GID-TA11150 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]

    Awaiting development Reference number: GID-TA11591 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development